STOCKWATCH
·
 Medicinal Chemicals and Botanical Products
Quarterly ResultMay 12, 2026, 04:32 PM

Upexi Q3 Net Loss $109.3M; Solana Holdings Up 9%; Debt Reduced

AI Summary

Upexi, Inc. announced its fiscal third-quarter results for March 31, 2026, reporting a net loss of $109.3 million, or $1.67 per share, primarily due to $92.3 million in unrealized digital asset losses. Despite the loss, the company increased its Solana token holdings by 9% and reduced short-term debt by $7.6 million. Total revenue grew to $4.6 million, and gross profit surged 179% year-over-year. The company also repurchased 2.5 million shares and completed a $36 million private placement.

Key Highlights

  • Net loss totaled $109.3 million, or $1.67 per share, for the fiscal third quarter.
  • Unrealized losses on digital assets accounted for $92.3 million of the net loss.
  • Solana tokens held increased by 9% (~189,000 tokens) during the quarter.
  • Total revenue for the quarter was $4.6 million, up from $3.2 million year-over-year.
  • Gross profit totaled $4.4 million, a 179% increase year-over-year.
  • Reduced short-term debt by approximately $7.6 million, including $5.4 million in treasury debt.
  • Repurchased approximately 2.5 million Upexi shares in the open market.
  • Cash and cash equivalents increased to $3.5 million as of March 31, 2026.
UPXI
Medicinal Chemicals and Botanical Products
UPEXI, INC.

Price Impact